SBL
MBVX

Sargent Bickham Lagudis’s MABVAX THERAPEUTICS HLDGS INC MBVX Stock Holding History

Sargent Bickham Lagudis’s Portfolio MBVX Stock Details MBVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1
Closed – – 827
2017
Q4 		$0 Hold
1
– – ﹤0.01% 860
2017
Q3 		$0 Hold
1
– – ﹤0.01% 847
2017
Q2 		$0 Hold
1
– – ﹤0.01% 829
2017
Q1 		$0 Buy
+1
New +$9 ﹤0.01% 794

Other funds holding MBVX

Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
BCM
Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

Sargent Bickham Lagudis's MBVX Position: Q1 2018 in Review

Sargent Bickham Lagudis sold out of MABVAX THERAPEUTICS HLDGS INC (MBVX) in Q1 2018, closing a stake of 1 share.

Sargent Bickham Lagudis first reported a position in MBVX in Q1 2017 and held it in 4 quarters. The position peaked at $0 in Q4 2017. 11 funds tracked by Wall St. Rank hold MBVX as of Q1 2018.

  • Sargent Bickham Lagudis reported no remaining MABVAX THERAPEUTICS HLDGS INC position as of Q1 2018 after selling out during the quarter.
  • Sargent Bickham Lagudis sold 1 MABVAX THERAPEUTICS HLDGS INC share in Q1 2018.
  • Sargent Bickham Lagudis first reported a position in MABVAX THERAPEUTICS HLDGS INC in Q1 2017 and held it in 4 quarters.
  • Sargent Bickham Lagudis's MABVAX THERAPEUTICS HLDGS INC position peaked at $0 in Q4 2017.
  • 11 funds tracked by Wall St. Rank held MABVAX THERAPEUTICS HLDGS INC as of Q1 2018.

Based on Sargent Bickham Lagudis's 13F filing for Q1 2018, filed 13 Sep 2021.